Based on the provided data, anti-infective medicine sales in South Korea are expected to show minimal growth from 2024 to 2028. In 2023, the value stood at $51.5 per capita. Forecasted values indicate a slight year-on-year increase of approximately 0.2% from 2024 to 2026 and an even smaller increment moving from 2026 to 2028, reflecting a plateau around $51.9 per capita.
Year-on-year variation:
- 2024: +0.2%
- 2025: +0.2%
- 2026: +0.2%
- 2027: +0.1%
- 2028: 0%
Last two years' trend:
- Minimal increment of 0.1-0.2% per year, indicating a steady but slow growth.
5-year CAGR:
- The compound annual growth rate over the last 5 years shows a very modest increase of approximately 0.2%.
Future trends to watch:
- Potential emergence of antibiotic resistance could spur demand for new medicines and slightly boost growth.
- Government healthcare policies and investments in medical research might affect future sales and innovation in anti-infective medicines.
